Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Investors purchased 4,063 put options on the company. This represents an increase of approximately 2,362% compared to the average volume of 165 put options.
Xenon Pharmaceuticals Trading Up 1.6 %
NASDAQ:XENE traded up $0.70 during mid-day trading on Thursday, hitting $43.15. The company had a trading volume of 419,299 shares, compared to its average volume of 411,194. The business has a fifty day simple moving average of $41.37 and a 200-day simple moving average of $40.22. Xenon Pharmaceuticals has a 1 year low of $33.62 and a 1 year high of $50.99.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.82) by $0.01. During the same period last year, the business posted ($0.73) earnings per share. Research analysts predict that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on XENE shares. HC Wainwright reiterated a "buy" rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 price objective on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. Wedbush lowered their target price on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an "outperform" rating for the company in a report on Friday, August 9th. Raymond James reaffirmed an "outperform" rating and set a $50.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Eleven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $57.45.
Get Our Latest Stock Analysis on Xenon Pharmaceuticals
Insider Buying and Selling
In other Xenon Pharmaceuticals news, Director Gary Patou sold 4,891 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total transaction of $200,922.28. Following the transaction, the director now owns 23,573 shares of the company's stock, valued at $968,378.84. This represents a 17.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 5.52% of the stock is owned by company insiders.
Institutional Trading of Xenon Pharmaceuticals
A number of hedge funds have recently made changes to their positions in XENE. FMR LLC grew its holdings in Xenon Pharmaceuticals by 2.2% during the 3rd quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company's stock valued at $272,349,000 after purchasing an additional 149,511 shares in the last quarter. Driehaus Capital Management LLC boosted its position in Xenon Pharmaceuticals by 2.3% in the 2nd quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company's stock valued at $172,315,000 after buying an additional 97,732 shares during the last quarter. Wellington Management Group LLP boosted its position in Xenon Pharmaceuticals by 0.4% in the 3rd quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company's stock valued at $151,317,000 after buying an additional 15,226 shares during the last quarter. Braidwell LP grew its stake in shares of Xenon Pharmaceuticals by 5.7% during the third quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company's stock valued at $106,585,000 after acquiring an additional 146,682 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Xenon Pharmaceuticals by 144.2% during the third quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company's stock worth $100,506,000 after acquiring an additional 1,507,135 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company's stock.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
